Pharmacokinetic/Pharmacodynamics Modeling of Drug-Loaded PLGA Nanoparticles Targeting Heterogeneously Vascularized Tumor Tissue
- 185 Downloads
Nanoparticle-mediated drug delivery and efficacy for cancer applications depends on systemic as well as local microenvironment characteristics. Here, a novel coupling of a nanoparticle (NP) kinetic model with a drug pharmacokinetic/pharmacodynamics model evaluates efficacy of cisplatin-loaded poly lactic-co-glycolic acid (PLGA) NPs in heterogeneously vascularized tumor tissue.
Tumor lesions are modeled with various levels of vascular heterogeneity, as would be encountered with different types of tumors. The magnitude of the extracellular to cytosolic NP transport is varied to assess tumor-dependent cellular uptake. NP aggregation is simulated to evaluate its effects on drug distribution and tumor response.
Cisplatin-loaded PLGA NPs are most effective in decreasing tumor size in the case of high vascular-induced heterogeneity, a high NP cytosolic transfer coefficient, and no NP aggregation. Depending on the level of tissue heterogeneity, NP cytosolic transfer and drug half-life, NP aggregation yielding only extracellular drug release could be more effective than unaggregated NPs uptaken by cells and releasing drug both extra- and intra-cellularly.
Model-based customization of PLGA NP and drug design parameters, including cellular uptake and aggregation, tailored to patient tumor tissue characteristics such as proportion of viable tissue and vascular heterogeneity, could help optimize the NP-mediated tumor drug response.
KEY WORDScancer nanotherapy cancer simulation mathematical modeling PLGA nanoparticles tumor heterogeneity
Non-small cell lung cancer
Poly lactic-co-glycolic acid
ACKNOWLEDGMENTS AND DISCLOSURES
HBF acknowledges partial support by the National Institutes of Health/National Cancer Institute Grant R15CA203605.
- 10.McClurg RB. Steady state homogeneous nucleation rate and primary particle size distribution. Abstr Pap Am Chem Soc. 2001;222:U198–U9.Google Scholar
- 23.van de Ven AL, Abdollahi B, Martinez CJ, Burey LA, Landis MD, Chang JC, et al. Modeling of nanotherapeutics delivery based on tumor perfusion. New J Phys. 2013;15.Google Scholar
- 27.Curtis LT, Rychahou P, Bae Y, Frieboes HB. A computational/experimental assessment of antitumor activity of polymer nanoassemblies for pH-controlled drug delivery to primary and metastatic tumors. Pharm Res. 2016.Google Scholar
- 28.Reichel D, Curtis LT, Ehlman E, Mark Evers B, Rychahou P, Frieboes HB, et al. Development of Halofluorochromic polymer nanoassemblies for the potential detection of liver metastatic colorectal cancer tumors using experimental and computational approaches. Pharm Res. 2017;34(11):2385–402.PubMedPubMedCentralCrossRefGoogle Scholar
- 48.Chamseddine IM, Frieboes HB, Kokkolaras M. Design optimization of tumor vasculature-bound nanoparticles. Scientific Reports. 2018; 8(1):17768.Google Scholar